Literature DB >> 7374679

Smoldering multiple myeloma.

R A Kyle, P R Greipp.   

Abstract

Entities:  

Mesh：

Year:  1980        PMID： 7374679     DOI： 10.1056/NEJM198006123022405

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  76 in total

1.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

2.  Antigen stimulated IgM secretion by circulating B lymphocytes in patients with benign and malignant IgG gammopathy. Relationship to stage of disease.

Authors:  S Pollack; R Katz; I Tatarsky; A Carter
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

3.  Osteosclerotic myeloma variants.

Authors:  F M Hall; S M Gore
Journal:  Skeletal Radiol       Date:  1988       Impact factor: 2.199

4.  p53 gene mutations in multiple myeloma.

Authors:  R G Owen; S A Davis; J Randerson; A C Rawstron; F Davies; J A Child; A S Jack; G J Morgan
Journal:  Mol Pathol       Date:  1997-02

Review 5.  Progress in the Management of Smoldering Multiple Myeloma.

Authors:  Timothy M Schmidt; Natalie S Callander
Journal:  Curr Hematol Malig Rep       Date:  2021-05-13       Impact factor: 3.952

Review 6.  Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Oncology (Williston Park)       Date:  2011-06       Impact factor: 2.990

7.  Immunoglobulin secretion by peripheral blood and bone marrow B cells in patients with multiple myeloma. Studies by the reverse haemolytic plaque assay.

Authors:  F Dammacco; A Vacca; E Altomare; N Campobasso
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

Review 8.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

9.  Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.

Authors:  Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby; Mauricio Pineda-Roman; Klaus Hollmig; Yazan Alsayed; Antje Hoering; Jackie Szymonifka; Elias Anaissie; Nathan Petty; Naveen S Kumar; Geetika Srivastava; Bonnie Jenkins; John Crowley; Jerome B Zeldis
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

10.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.